← Back to VTS Methodology
VTS Scoring Log

GenX Peptides

genx.bio · Est. 2013 · Houston, TX · Scored August 2026

GenX Peptides was founded in 2013 and is one of the longest-operating research peptide vendors in the US market. The site at genx.bio is publicly accessible. The About page describes HPLC and mass spectrometry testing and states the company is an "accredited quality assurance provider" - no testing laboratory is named anywhere on the site. Third-party review sources identify MZ Biolabs as the testing lab, but this is not confirmed on the vendor's own pages. No public COA library is hosted on the site. GenX was added as a named respondent in Eli Lilly's USITC trademark investigation regarding tirzepatide false designation of origin on May 21, 2024 - the same Inv. No. 337 investigation in which Strate Labs was also named. The 13-year operational track record is the strongest single scoring factor for this vendor, but is materially offset by the USITC enforcement context and the absence of any publicly verifiable documentation.

35 /100
Low
Est. 2013, one of the longest track records in the VTS catalog. MZ Biolabs identifiable via third-party sources but not named on own site. No public COA library. Named in Eli Lilly USITC false designation of origin investigation (May 2024). The documentation gaps are the primary score driver.
Dimension Scores
DimensionMaxNotesScore
Third-Party Testing Practice 30 HPLC and mass spectrometry testing described on the About page as the standard testing methodology. The About page describes GenX as an "accredited quality assurance provider" without naming the accrediting body. Third-party review sources (Peptide Protocol Wiki) identify MZ Biolabs as the testing lab. MZ Biolabs is not named on the vendor's own site. VTS credits the externally identified lab partially; the absence of lab disclosure on the vendor's own pages limits the score. MZ Biolabs standard service excludes sterility and endotoxin testing. 12/30
Batch Traceability & Verification 20 No public COA library, no lot-searchable database, and no COA examples visible on the public-facing site. Third-party review sources note that COAs are available, but no batch traceability system is accessible publicly. Partial credit for the stated testing program and the external identification of MZ Biolabs, which has a verifiable DEA registration. 6/20
COA Accessibility 15 No public COA library hosted on genx.bio. No COA examples on product pages. COAs appear to be provided with orders per third-party review sources. Request-only or with-order COA access scores equivalently to email-on-request under VTS methodology. Minimal credit for the claimed availability. 3/15
COA Completeness 15 HPLC and mass spectrometry confirmed via About page and third-party sources. MZ Biolabs standard service scope applies if the lab identification from third-party sources is accurate: HPLC purity and identity confirmation, no sterility or endotoxin panels. No public COA to review for completeness. 6/15
Testing Recency 10 No dated COAs publicly accessible. Operation since 2013 implies ongoing testing across a 13-year catalog. No evidence of stale documentation confirmed from public sources. Moderate credit for a long-running vendor without documented recency gaps. 4/10
Policy Transparency 5 Shipping & Returns page publicly linked at /shipping-and-returns/. Houston, TX is mentioned in third-party records as the operating location but no address appears on the public site. GenX was named as a respondent in Eli Lilly's USITC tirzepatide trademark investigation for false designation of origin (added May 21, 2024, Inv. No. 337-TA-1377). This is a documented public record from the ITC docket. The investigation's status and resolution are factual records that affect the Policy Transparency score, as they represent a verifiable legal finding about product labeling integrity. 1/5
Operational Track Record 5 Est. 2013, approximately 13 years of operation - among the longest in the VTS catalog alongside PureRawz. Houston, TX identified as operating location in third-party records. A 13-year operational history is a meaningful signal in a market where vendors appear and close within months. The USITC enforcement context (named respondent for false designation of origin) offsets the track record credit and limits this score from the maximum. 3/5
Total 35/100
Community Signal
Independent Test Results
No community-commissioned independent test results identified in publicly accessible forums at the same volume as higher-documented vendors. Trustpilot shows a small number of reviews. Community reputation in budget peptide forums generally positive for pricing and fulfillment. This field will be updated as independently sourced results are formally documented.
USITC Enforcement Context
GenX was added as a named respondent in Eli Lilly's USITC complaint regarding tirzepatide false designation of origin on May 21, 2024 (Inv. No. 337-TA-1377). The investigation covered GLP-1 agonist tirzepatide trademark infringement and false designation of origin. Other named respondents in the same investigation include Strate Labs (which closed July 1, 2026) and several other vendors. The specific resolution of the GenX portion of this case is a matter of public ITC record accessible through the ITC's Electronic Document Information System (EDIS). This is a factual legal record, not a characterization of product quality.
Scoring Notes
13 years is a real signal - the documentation gaps are the problem
A vendor that has operated continuously since 2013 in a market where most vendors close within two years has demonstrated operational durability that shorter-lived peers cannot match. The VTS score reflects the absence of publicly verifiable documentation, not a judgment about the vendor's longevity. A public COA library with the MZ Biolabs name explicitly stated would materially improve the score.
Lab named in third-party sources but not on own site
MZ Biolabs is identified as the GenX testing lab in multiple third-party review sources. VTS applies partial credit for the external lab identification. The standard under VTS methodology is for the lab to be named on the vendor's own site - as vendors like Ion Peptides, Peptide Crafters, and NuScience Peptides do. The indirect disclosure path is documented here as a finding; it is not treated as equivalent to a direct named-lab disclosure on the vendor's own pages.